News
Renovo Rx, Inc. 2025 Annual Report 10-K/A " Key Risks, Regulatory Challenges, and Strategic Focus in Drug Development 15
4+ hour, 11+ min ago (512+ words) Minichart Renovo Rx, Inc. 2025 Annual Report 10-K/A " Key Risks, Regulatory Challenges, and Strategic Focus in Drug Development 15 Renovo Rx Files Amended 10-K/A: Key Risk Factors, Strategic Uncertainty, and Financial Position Detailed Renovo Rx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical…...
Baiwang Co. , Ltd. Signs Industry-Academia-Research Cooperation Agreement with Zhongguancun Academy and Institute of Artificial Intelligence to Advance Data Intelligence and AI Applications 1
1+ hour, 50+ min ago (328+ words) Minichart Baiwang Co. , Ltd. Signs Industry-Academia-Research Cooperation Agreement with Zhongguancun Academy and Institute of Artificial Intelligence to Advance Data Intelligence and AI Applications 1 Baiwang Co. , Ltd. Announces Strategic AI Partnership with Zhongguancun Institutions - Baiwang Co. , Ltd. has entered into a…...
Apollo Commercial Real Estate Finance, Inc. Files Form 8-K with SEC " Company Information and Key Details
3+ hour, 49+ min ago (261+ words) Apollo Commercial Real Estate Finance, Inc. , a real estate investment trust listed on the New York Stock Exchange under the ticker ARI, has announced the departure of a key board member, Scott S. Prince. Prince will not be seeking re-election at…...
Traws Pharma Secures $60 M Financing, Advances Tivoxavir Marboxil for Influenza and Hantavirus Programs in Q1 2026 Financial Results " Minichart
11+ hour, 20+ min ago (471+ words) Traws Pharma Secures $60 M Financing, Advances Tivoxavir Marboxil for Influenza and Hantavirus Programs in Q1 2026 Financial Results Minichart Traws Pharma Secures $60 M Financing, Advances Tivoxavir Marboxil for Influenza and Hantavirus Programs in Q1 2026 Financial Results Traws Pharma Q1 2026 Business and Financial Update Key…...
Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies " Minichart
6+ hour, 31+ min ago (276+ words) Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies Minichart Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies Polaryx Therapeutics, Inc. Q1 2026 Investor Report: Key Highlights…...
Vivakor Closes $12 Million Institutional Offering to Advance Houston Remediation Processing Center and Reduce Debt
19+ hour, 1+ min ago (16+ words) Minichart...
American Strategic Investment Co. Q1 2026 Highlights: Manhattan-Focused Real Estate Portfolio, Investment Grade Tenants, and Strong Fixed-Rate Debt Structure
12+ hour, 1+ min ago (372+ words) Minichart American Strategic Investment Co. Q1 2026 Highlights: Manhattan-Focused Real Estate Portfolio, Investment Grade Tenants, and Strong Fixed-Rate Debt Structure American Strategic Investment Co. (ASIC) First Quarter 2026 Investor Update: Key Highlights and Price-Sensitive Developments American Strategic Investment Co. (ASIC) has released its…...
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing
8+ hour, 44+ min ago (411+ words) Minichart We value your privacy No cookies to display. Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features. Advertisement cookies are used to provide visitors with…...
Palvella Therapeutics Reports Positive Phase 2 TOIVA Trial Results for QTORIN Rapamycin in Cutaneous Venous Malformations at SID 2026
11+ hour, 38+ min ago (225+ words) Minichart We value your privacy No cookies to display. Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features. Advertisement cookies are used to provide visitors with…...
Mi NK Therapeutics Initiates Phase 2 Trial for agen T-797 in Acute Lung Injury, Reports Q1 2026 Results and Advances i NKT Cell Therapy Platform
12+ hour, 38+ min ago (676+ words) Minichart Mi NK Therapeutics Initiates Phase 2 Trial for agen T-797 in Acute Lung Injury, Reports Q1 2026 Results and Advances i NKT Cell Therapy Platform Mi NK Therapeutics Reports Q1 2026 Results: Advances in i NKT Cell Therapy, New Clinical Data, and Strategic Collaborations Mi…...